Article Text

other Versions

PDF

Serum KL-6 Differentiates Neuroendocrine Cell Hyperplasia of Infancy From the Inborn Errors of Surfactant Metabolism
  1. Minh L Doan (minhluan.doan{at}amedd.army.mil)
  1. Department of Pediatrics, Tripler Army Medical Center, United States
    1. Okan Elidemir (oxelidem{at}texaschildrens.org)
    1. Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, United States
      1. Megan K Dishop (mkdishop{at}texaschildrens.org)
      1. Department of Pathology, Baylor College of Medicine, Texas Children's Hospital, United States
        1. Haibin Zhang (haibinz{at}bcm.tmc.edu)
        1. Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, United States
          1. E O'brian Smith (esmith{at}bcm.tmc.edu)
          1. Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, United States
            1. Phil Black (pblack{at}cmh.edu)
            1. Department of Pediatrics, University of Missouri at Kansas City, Children’s Mercy Hospital, United States
              1. Robin Deterding (deterding.robin{at}tchden.org)
              1. Department of Pediatrics, University of Colorado Health Science Center, Children’s Hospital, United States
                1. Dion Roberts
                1. Pediatric Breathing Disorders Clinic, United States
                  1. Leland L Fan (llfan{at}texaschildrens.org)
                  1. Department of Pediatrics, Baylor College of Medicine, Texas Children's Hospital, United States

                    Abstract

                    Background: We sought to determine if KL-6 is a useful biomarker in differentiating neuroendocrine cell hyperplasia of infancy (NEHI), a benign form of children’s interstitial lung disease, from the more severe inborn errors of surfactant metabolism (IESM), since their clinical presentation can be similar.

                    Methods: Serum KL-6 levels were measured in 10 healthy control children, 6 with NEHI and 13 with IESM (4 with surfactant protein C and 9 with ABCA3 mutations). The initial clinical presentation, findings on previous CT scans, and ILD scores at the time of KL-6 testing were compared. Correlations between KL-6 levels with age and with interval from lung biopsy were evaluated.

                    Results: The median (range) KL-6 levels were 265 (1-409), 194 (47-352), 1149 (593-4407) and 3068 (726-9912) for the control, NEHI, SP-C and ABCA3 groups, respectively. When compared to the control and NEHI groups, median KL-6 levels were significantly higher in the SP-C (p<0.01; p=0.01, respectively) and ABCA3 groups (p<0.001; p=0.001, respectively); however, there was no difference between the control and NEHI groups (p=0.91). An inverse relationship was seen between KL-6 levels and age in the IESM group, but not in the NEHI or control groups. Children with NEHI had similar presenting clinical manifestations and were equally symptomatic at the time of KL-6 measurement as those with IESM.

                    Conclusions: Children with NEHI have normal KL-6 levels, in contrast to those with IESM, who have elevated serum KL-6 levels; serum KL-6 may be a useful biomarker in distinguishing between these entities when their clinical presentations overlap.

                    Statistics from Altmetric.com

                    Request permissions

                    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.